Licensing · MENA · Announced 14 Sept 2026
Nordic Pharma → Jamjoom Pharma
Licensing deal between Nordic Pharma (Netherlands) and Jamjoom Pharma (Saudi Arabia), covering Lacrifill® Canalicular Gel, announced 14 Sept 2026. Value: Undisclosed.
Parties: Nordic Pharma (Netherlands) → Jamjoom Pharma (Saudi Arabia)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- Middle East & Africa (MEA) — exclusive; MEA availability conditional on local regulatory registration in each market
- Therapeutic area
- Ophthalmology
- Asset
- Lacrifill® Canalicular Gel (cross-linked hyaluronic acid gel for canalicular occlusion in dry eye disease)
- Announced
- 14 Sept 2026
Our analysis
Why this matters
This is a textbook "category king buys category leadership" deal. Jamjoom Pharma — Saudi Arabia's decades-old ophthalmology franchise — has taken exclusive MEA rights to Lacrifill®, Nordic Pharma's novel canalicular gel for dry eye disease. Dry eye accounts for 41% of the MEA ophthalmology market, a roughly $200 million regional opportunity where Jamjoom already holds the #1 position with over 15% share. This deal is not market entry; it is a leader consolidating a segment with a differentiated next-generation asset before competitors can.
The full analysis is free to read with a work email on this page.
Source: DEAL ROOM